Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Dover Corp (DOV) vs Moderna, Inc. (MRNA) Price & Performance

Dover CorpTrade
Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

Dover Corp vs Moderna, Inc. — how do they compare? Dover Corp trades at $208.42 (market cap $28.07B), while Moderna, Inc. trades at $63.74 (market cap $24.18B). The key difference: Dover Corp is the larger of the two by market cap, and Dover Corp pays a 1.01% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.

DOVMRNA
Market Cap
$28.07B$24.18B
Sector
IndustrialsHealth
52-Week High
$233.31$81.80
52-Week Low
$161.16$22.36
Enterprise Value
$29.58B$20.33B
Dividend Yield
1.01%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Dover Corp

Dover Corporation (DOV) trades at $210.1, down 0.49% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported strong Q2 2026 results with EPS of $2.74, exceeding expectations, and raised full-year guidance. Recent dividend increases and strategic acquisitions, such as Cloeren, highlight management's confidence in growth. Valuation ratios like P/E of 25.21 and ROE of 14.98% reflect solid profitability, though the stock faces resistance near $212.

The outlook for DOV is positive, driven by robust fundamentals and analyst consensus favoring a buy rating with a $232.33 price target. Risks include market volatility and execution challenges from acquisitions, but diversified end-market exposure and margin expansion support upside potential for investors seeking steady income and growth.

Moderna, Inc.

Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.

Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Dover Corp

Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.

Read more on DOV

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA